AAA
BPMC

Affinity Asset Advisors’s Blueprint Medicines BPMC Stock Holding History

Affinity Asset Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-250,000
Closed -$32M – 101
2025
Q2 		$32M Buy
+250,000
New +$26M 4.38% 5
2022
Q2 		– Sell
-1,988
Closed -$127K – 57
2022
Q1 		$127K Buy
+1,988
New +$143K 0.02% 57

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Affinity Asset Advisors's BPMC Position: Q3 2025 in Review

Affinity Asset Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 250,000 shares — an estimated $32M sold.

Affinity Asset Advisors first reported a position in BPMC in Q1 2022 and held it in 2 quarters. The position peaked at $32M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Affinity Asset Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 Blueprint Medicines shares in Q3 2025, an estimated $32M.
  • Affinity Asset Advisors first reported a position in Blueprint Medicines in Q1 2022 and held it in 2 quarters.
  • Affinity Asset Advisors's Blueprint Medicines position peaked at $32M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.